Multiple Myeloma section

Multiple Myeloma News & Features

Circulating RNA may provide prognostic tool for multiple myeloma

The molecular mail sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study presented at ASH. The findings may ultimately guide doctors in deciding which therapies are best for individual patients with myeloma.

ASH: Carfilzomib increases survival in relapsed multiple myeloma

ASH: Carfilzomib increases survival in relapsed multiple myeloma

Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.

New potential therapeutic agents for myeloma are on the horizon

New potential therapeutic agents for myeloma are on the horizon

Recent therapeutic progress has improved outcomes for patients with myeloma; however, the complex biology of this disease continues to challenge treatment.

New drug for multiple myeloma to begin clinical trial

New drug for multiple myeloma to begin clinical trial

A new drug in development, known as DTP3, has killed myeloma cells in laboratory tests in human cells and mice.

Calcium isotope analysis predicts myeloma progression

Researchers believe that a staple of Earth science research can be used in biomedical settings to predict the course of disease.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs